Particle.news
Get it on Google Play
Download on the App Store
19 ARTICLES
·
last wk.

Novo Nordisk to Cut U.S. List Prices for Wegovy, Ozempic and Rybelsus to $675 in 2027

The move aims to lower out-of-pocket costs for insured patients whose payments are tied to list prices.

Image
Cutting Healthcare Costs A businesswoman cutting the high price of healthcare tag with large scissors over an abstract background. The woman, scissors and price tag are on a separate layer from the background.
Image
Image

Overview

  • Effective January 1, 2027, the new wholesale acquisition cost will be $675 per month for all doses of Wegovy, Ozempic and Rybelsus, covering both injectable and oral forms.
  • Novo Nordisk says the cuts equate to roughly 50% off Wegovy and 35% off Ozempic compared with current list prices.
  • The company states the change targets people in high-deductible or co-insurance plans and does not alter direct-to-consumer or self-pay prices.
  • The pricing shift follows intensifying competition from Eli Lilly and recent signs of pressure on Novo Nordisk’s sales outlook and late-stage trial results for a next-generation drug.
  • The announcement comes in a policy environment shaped by TrumpRx.gov deals and Medicare pricing under the Inflation Reduction Act, even as many cash buyers already access lower DTC prices such as $349 for Wegovy.